Literature DB >> 10734698

Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific Region, 1998. The WHO Western Pacific Gonococcal Antimicrobial Surveillance Programme.

J W Tapsall1.   

Abstract

Effective treatment of gonorrhoea in the World Health Organization's Western Pacific Region is hampered by the emergence and spread of antibiotic resistant strains of Neisseria gonorrhoeae. A programme of surveillance of gonococcal susceptibility to antibiotics (GASP) continued in the region in 1998. A high proportion of isolates in many participating countries was resistant to quinolones and penicillins, continuing trends observed by this programme since 1992. Resistance to the later generation cephalosporins and to spectinomycin was absent or infrequent. Options for effective treatment of gonorrhoea in the region have been severely compromised by antibiotic resistance.

Entities:  

Mesh:

Year:  2000        PMID: 10734698

Source DB:  PubMed          Journal:  Commun Dis Intell        ISSN: 0725-3141


  4 in total

1.  In-house growth-promoting transport system for Neisseria gonorrhoeae.

Authors:  Dharmendra Sharma; Sunil Sethi; Swami Das Mehta; Meera Sharma
Journal:  J Clin Microbiol       Date:  2007-05-30       Impact factor: 5.948

Review 2.  Integrated Multilevel Surveillance of the World's Infecting Microbes and Their Resistance to Antimicrobial Agents.

Authors:  Thomas F O'Brien; John Stelling
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

3.  Update on Quinolone Resistance in Neisseria gonorrhoeae.

Authors:  Jonathan M. Zenilman
Journal:  Curr Infect Dis Rep       Date:  2002-04       Impact factor: 3.725

Review 4.  The Prevalence of Antimicrobial Resistant Neisseria gonorrhoeae in Papua New Guinea: A Systematic Review and Meta-Analysis.

Authors:  Barne Willie; Emma L Sweeney; Steven G Badman; Mark Chatfield; Andrew J Vallely; Angela Kelly-Hanku; David M Whiley
Journal:  Int J Environ Res Public Health       Date:  2022-01-28       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.